The Food and Drug Administration’s approval of a generic version of mifepristone, a drug used in chemical abortions, isn’t just another bureaucratic misstep. It’s a profound betrayal of pro-life Americans and a reckless disregard for public safety.

The agency has now accelerated the mass production of a drug that ends unborn lives and carries serious risks for women. In doing so, the FDA’s bureaucracy has made clear that it serves ideological interests, not the citizens or the administration it is supposed to answer to.

Every life matters — both the woman and the child. Without moral clarity in policy, America risks losing its foundation altogether.

Only days before the approval, FDA Commissioner Marty Makary publicly pledged to conduct a full safety review of mifepristone. That commitment lasted less than a week. By fast-tracking the generic drug, the agency reversed its own position without completing the promised review.

Mifepristone is no ordinary medication. It is designed to be 100% lethal to an unborn child and carries documented risks to the mother, including severe bleeding and infection. The FDA’s reversal isn’t a matter of procedure — it’s a moral failure dressed up as administrative routine.

For millions of Americans who value the sanctity of life, this decision feels like déjà vu: another Washington agency disregarding its duty under the cover of “regulatory process.”

The bureaucracy’s excuse doesn’t hold

Pro-life Americans — one of the largest and most enduring constituencies in the nation — have been ignored by the bureaucratic elite for decades. When confronted, officials claim they’re merely “following the law.” But the FDA has wide discretion to delay or deny authorization for drugs that raise ethical or safety concerns.

Choosing not to use that authority isn’t neutrality. It’s cowardice. It’s the decision to shrug and look away while a drug designed to end life gains wider reach.

This approval darkens what should have been a pro-life administration’s legacy. Mifepristone’s purpose could not be clearer: It ends human life. Authorizing a generic version without exhaustive review prioritizes ideology over science and convenience over conscience.

Between promise and practice

The FDA insists that further studies will follow, but the promise rings hollow. As 17 U.S. senators recently pointed out, the safety study Makary pledged during his confirmation took six months to even be announced — and was done quietly, with little public notice.

RELATED: Trump’s battle for the abortion pill — and why it’s more dangerous than you’ve been told

Photo by Anna Rose Layden/Getty Images

That delay reveals the real problem: a deep-state bureaucracy operating with impunity, detached from the leadership and values of the nation it serves. When bureaucrats make decisions that contradict both policy and conscience, accountability becomes nonnegotiable.

A call to accountability and courage

The FDA must immediately identify and remove the officials responsible for this approval. It should also reconsider mifepristone’s production and distribution altogether. A drug designed to end life has no place in a nation that claims to defend the vulnerable.

The stakes could not be higher. Every life matters — both the woman and the child. Without moral clarity in policy, America risks losing its foundation altogether.

This moment demands courage, not compliance. Those who value life must stand firm, demand accountability, and work toward a future where the institutions of government defend life instead of destroying it.

​Opinion & analysis, Abortion, Pro-life, Food and drug administration, Mifepristone abortion pill, Mifepristone, Congress, Safety, Deep state, Administrative state, Families, Children, Donald trump, Marty makary, Regulations 

The Trump administration has made Main Street a central priority — and limiting the reach of the Corporate Transparency Act’s Beneficial Ownership Information rule was one of its best decisions so far. The rule required small businesses to hand over sensitive ownership data to the Treasury Department’s Financial Crimes Enforcement Network, under threat of heavy fines and criminal penalties. Large corporations were mostly exempt.

After small-business owners and pro-business lawmakers protested, the administration moved quickly. In March, it issued an interim rule exempting U.S. small businesses and citizens from the reporting mandate. Treasury then opened a public comment period to shape a final rule. That comment window closed five months ago, and yet the final rule still hasn’t arrived.

The administration must not allow deep-state bureaucrats and bad actors to stall this reform. Small businesses need clarity and relief — now, not after another election cycle.

Small-business owners want the exemption locked in for good — not left vulnerable to reversal by a future administration. Ohio Republican Rep. Warren Davidson’s Repealing Big Brother Overreach Act, with nearly 200 co-sponsors, aims to make that exemption permanent. But some lawmakers say they can’t codify until Treasury finalizes the rule. The delay is holding back certainty for millions of entrepreneurs.

Many of those same business owners also want FinCEN to purge the personal data they already submitted before the exemption took effect. With hacking and misuse always possible, they’re demanding the government delete the information it never should have collected.

FinCEN Director Andrea Gacki acknowledged the concern during a congressional hearing. “Along with the resolution of this rule, we also intend to resolve questions around the data that we have collected and dispose of data that is no longer legally required,” Gacki said.

A purge appears to be on the table — but without urgency from Treasury, the data remains at risk.

Gacki told Congress the rule would be finalized “in the upcoming year.” Whether that means 2025 or 2026 is anyone’s guess. The longer the Treasury Department drags its feet, the closer we get to the midterms — and the less likely Congress is to act in time.

Brian Reardon, president of the S Corporation Association, put it bluntly: “Intentions are well and good, but we need action. Sixteen million small businesses filed their owners’ personal information under the old rules. The only way to protect that information is to purge the database now.”

RELATED: Europe shows us what happens when bureaucrats win

wassam siddique via iStock/Getty Images

The National Federation of Independent Business agrees. NFIB’s Josh McLeod said, “President Trump was right to call BOI egregious, invasive, and an economic menace. Unfortunately, a future administration can simply rewrite this burdensome mandate back into existence. Small businesses urgently need the Trump administration and Congress to repeal the CTA and destroy the data.”

Small businesses remain the backbone of the U.S. economy. Reducing legal uncertainty and lifting needless regulatory burdens should stay at the top of Congress’ agenda. Finalizing the CTA BOI rule — and permanently securing the exemptions for small businesses and citizens — is an easy, commonsense win for Main Street.

The Trump administration must not allow deep-state bureaucrats and bad actors to stall this reform. Small businesses need clarity and relief — now, not after another election cycle.

​Opinion & analysis, Wall street, Main street, Treasury department, Financial crimes enforcement network, Fincen, Corporations, Small business, Regulations, Corporate transparency act, Beneficial ownership information rule, Andrea gacki, Warren davidson, Uncertainty, Rules and regulations, National federation of independent business, Congress, Donald trump, Deep state, Administrative state, Economy